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Radiological exposure of patients undergoing transcatheter
aortic valve implantation in contemporary practice
Luigi Biascoa, Giovanni Pedrazzinia, Ole De Backerb, Catherine Klersyc,
Luca Bellesid, Stefano Presillad, Matteo Badinia, Francesco Faletraa,
Elena Pasottia, Enrico Ferraria, Stefanos Demertzisa, Tiziano Moccettia,
Davide Avianoa and Marco Moccettia
Background Radiological exposure associated with
transcatheter aortic valve implantation (TAVI) is unknown
and might impact on broadening indications to lower risk
patients. Radiological exposure of TAVI patients and its
predictors are herein reported.
Methods Radiological exposure derived from exams/
procedures performed within 30 days preceding/following
TAVI were acquired and converted into effective-dose. Total
effective-dose was defined as the sum of each single dose
derived from diagnostic/therapeutic sources. Univariable
and multivariable analyses were performed to recognize
correlates of exposure.
Results Seventy-five patients aged 82.6W6.0 years with a
median Euroscore II 3.6 [IQR 1.93–6.65] were analysed.
Median total effective-dose was 41.39 mSv [IQR 27.93–
60.88], with TAVI accounting for 47% of it. Age (coefficient
S0.031, 95% CI S0.060 to S0.002; PU0.031) and previous
history of cerebrovascular accidents (CVA; coefficient
S0.545; 95% CI S1.039 to S0.010; PU0.046) resulted
as inversely correlated to total effective-dose
(log-transformed), whereas left ventricular ejection fraction
(LVEF) less than 50% (coefficient 0.430, 95% CI 0.031–
0.828; PU0.035) was directly associated.
Conclusion Multiple radiological sources are responsible
for the observed exposure, with TAVI being the prominent
source. Age is inversely related to the radiological exposure.
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Introduction
The introduction of techniques allowing the percutane-
ous replacement of a stenotic aortic valve represented
one of the major advancements of interventional cardiol-
ogy in recent years.
Transcatheter aortic valve implantation (TAVI) was orig-
inally offered as an alternative to medical therapy in
elderly patients at extreme or high surgical risk. Its huge
therapeutic potential allowed the demonstration of, on
short-term outcomes, a reduction in mortality in nono-
perable patients and noninferiority to surgery in high-risk
patients.1,2
Justified by that initial evidence, an exponential
increase in procedures was observed,3 this was associ-
ated with a progressive widening of the indications,
resulting in a concomitant decrease in patient’s com-
plexity.4–6
Thus, future adoption of this technique as the therapy
of choice for an all-comer population with severe aortic
stenosis seems to be a potential perspective,7 also
justified by the great advances obtained in the opti-
mization of procedural outcomes.8
Nonetheless, almost no relevance has been given so far to
the amount and potential long-term effects of X-ray
exposure during TAVI, an aspect considered of little
clinical significance, due to the presumed low risk of
clinically evident effects.
Few retrospective analyses report on the procedural
radiological exposure of those patients, neglecting that
a complex preprocedural work-up and postprocedural
phasemight significantly impact on the total exposure.9,11
In light of a more widespread use of TAVI in younger
patients, radiological exposure cannot be disregarded any
longer, needs to be provided as a part of the information
given to patients and has to play a role in the decision
between TAVI vs. traditional surgical approaches.
Thus, the aim of this article is to describe the total
radiological exposure observed in a contemporary series
of TAVI patients and to recognize predictors of
increased exposure.
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Methods
Patient population
All patients with severe symptomatic aortic valve stenosis
with complete data on the fluoroscopic exposition who
have been treated with TAVI procedures at our Institu-
tion between 1 January 2015 and 31 May 2016 were
considered in the present analysis. Clinical data and
procedural details were prospectively collected according
to Swiss TAVI Registry requirements, and analysed. Data
on radiological exposure derived from all exams/proce-
dures performed within 30 days preceding/following the
implant procedure have been acquired from the on-site
data system. Written informed consent for the TAVI
procedure and data acquisition were signed by
all patients.
Patient workflow
Before final candidacy for TAVI, surgery or medical
therapy, each patient has to undergo a definite prepro-
cedural work-up in order to confirm the clinical indica-
tion, plan the procedure and foresee potential challenges.
Transthoracic and transoesophageal echocardiography as
well as a diagnostic coronary angiography and a contrast-
enhanced computed tomography (CT) scan are per-
formed in all suitable patients before heart team discus-
sion. Additional radiological examinations/procedures
(e.g. chest X-ray, adjunctive CT scan, unplanned coro-
nary angiography, pacemaker implantation, etc.) are per-
formed both preprocedurally and postprocedurally, when
deemed clinically necessary.
In patients with an estimated glomerular filtration rate
less than 40ml/kg/min, angiographic examinations are
reduced to the strictly necessary, withholding angio
CT scans in the vast majority of cases and echo data
are used to plan the procedure.
Coronary angiography
Coronary angiography is performed through the radial
access with a set of three cine projections for the right
coronary artery and six for the left. When TAVI is
considered as an option, aortography (LAO 308) and an
angiography in the AP projection of the iliofemoral vessel
is also performed. When revascularization is deemed
necessary, percutaneous coronary interventions (PCI)
are performed on the same or on a staged procedure.
Both for cine and fluoroscopy frame, the rate is set at
15 frame/s and all images are acquired on a Philips Allura
Clarity X-ray unit (Philips, Best, The Netherlands).
Regular calibration of the radiological equipment
was performed.
Computed tomography scan
Preprocedural CT imaging is performed on a 128 detec-
tors dual-source CT (Somatom Force; Siemens Health-
care, Forchheim, Germany) to evaluate the anatomy of
the aortic annulus and access vessels using a prespecified
protocol.12 An ECG-triggered high-pitch spiral acquisi-
tion is performed (250ms gantry rotation, 66ms temporal
resolution, 2 192 0.6 collimation, tube voltage 120 kV,
tube current 350–500mA depending on weight). Scan
direction is craniocaudal from above the aortic arch to
below the hip. After a test bolus to evaluate the contrast
agent transit time, 80ml of dye is injected in an ante-
cubital vein with a flow rate of 5ml/s. Images are recon-
structed using a slice thickness of 0.6mm, and an
increment of 0.4mm.
On the basis of CT scan data, annular dimensions are
measured and navigability of the ileofemoral arteries is
ascertained. The angiographic projection showing the
three hinge points of the aortic cusps is searched and
suggested to the interventional cardiologist as a potential
implant view.12
Transcatheter aortic valve implantation procedure
All procedures have been performed in a hybrid room
with an Allura Philips fluoroscopy system by a team of
four operators with expertise on coronary and structural
interventions. Each operator had a personal background
of more than 200 TAVI implants. Procedures were per-
formed with a standard fluoroscopy-guided implant pro-
cedure. Fluoroscopic acquisition was set at 15 f/s. The
reliability of the implant view predicted with CT scan
was ascertained with a cine aortography. In case of
unsatisfactory alignment, another implant view by means
of multiple angiographies was chosen.
Release of retrievable valves was performed during con-
tinuous fluoro imaging or cine recordings with repeated
dye injections to constantly monitor the valve position.
For balloon expandable valves, balloon inflation and
deflation were recorded with cine.
Effective-dose estimation
The equation ED¼OQCF, where OQ¼ operational
quantity, and CF¼ conversion factor were used for the
estimation of the effective-dose.
To convert the dose area product data provided by angio-
graphic equipment, the CF of 0.24mSv/Gycm2 published
byKarambatsakidou et al.10 was used, whereas for the dose
length product conversion the CFs published by Deak
et al. were used.13 CF used to calculate effective-dose for
traditionalX-ray examinationswere derived fromHeron.14
Total effective-dose was defined as the sum of each
single effective-dose derived from diagnostic or thera-
peutic sources in the 30 days preceding or following the
TAVI procedure.
Statistical analysis
Data are described as mean and standard deviation or the
median and interquartile range (IQR) if continuous, and
counts and percentage if categorical. Generalized linear
regression models to identify correlates of total effective-
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dose were used; given the skewed distribution, the latter
was log-transformed. All noncollinear variables with a P
less than 0.1 at the univariable analysis were included in a
multivariable model. The choice between collinear pre-
dictor was based on clinical knowledge. A model fit was
graphically assessed by using residuals. A two-sided P
value less than 0.05 was considered statistically signifi-
cant. Stata 14 (StataCorp, College Station, Texas, USA)
was used for computations.
Results
Patient population
Seventy-five patients with a mean age of 82.6 6.0 years
and an intermediate-to-low surgical risk (median Euro-
score II 3.6 [IQR 1.93–6.65]) treated with TAVI at our
site were evaluated. Baseline clinical and echocardio-
graphic characteristics are reported in Table 1.
All except one patient underwent a preprocedural coro-
nary angiography during the work-up phase: in 10 cases
(13.3%) coronary angiography was followed by PCIs
whereas in one patient, a balloon aortic valvuloplasty
was performed as a bridge to TAVI. In 66 cases (88%),
a contrast-enhanced CT angiography was performed.
The vast majority of TAVI were performed through a
percutaneous transfemoral approach (92%). In about two-
thirds of cases, a self-expandable valve was implanted. An
overall low complication rate was observed with one
intraprocedural death. In two cases, surgical repair of
the femoral artery was needed; no peripheral interven-
tions to repair access site complications, that could have
significantly increased exposure were performed. Table 2
reports on the details related to the TAVI procedure.
During the postprocedural phase, a repeated angio-
graphic examination was deemed necessary in two
patients, whereas a percutaneous mitral valve repair
and a percutaneous mitral valve dilatation were per-
formed in two distinct patients.
Radiological exposure
Table 3 shows the radiological exposure derived from
diagnostic sources, therapeutic procedures and TAVI
implantation.
The median total effective-dose of patients treated with
TAVI was 41.39mSv [IQR 27.93–60.88]. Distribution of
total radiological exposure was skewed with 86% receiv-
ing less than 100mSv and 10 patients showing an expo-
sure greater than 100mSv (Fig. 1).
TAVI implant resulted as the prevalent source of radio-
logical exposure, with a median effective-dose of
16.11mSv [IQR 10.54–27.70] per procedure, accounting
for almost half of the total exposure.
Contrast-enhanced cardiac and angio CT scans were
performed in 88% of patients, whereas other CT scans
were needed in the preprocedural or postprocedural
phase in 22.6% of patients (cerebral CT scan in 15,
Radiological exposure of patients undergoing TAVI Biasco et al. 581
Table 1 Patients’ clinical characteristics
Clinical characteristics
Patients, (n) 75
Male sex, n (%) 43 (57.3)
Age, years 82.66.0
Height, cm 164.38.9
Weight, kg 71.913.7
BMI 26.64.7
BMI >30, n (%) 20 (26.6)
Body surface area, m2 1.80.2
Comorbidities
Diabetes, n (%) 23 (30.6)
Hypertension, n (%) 67 (89.3)
End stage renal failure, n (%) 1 (1.3)
Creatinine (mmol/l), meanSD 11061
eGFR (ml/min/1.73 m2), meanSD 5225
Dyslipidaemia, n (%) 51 (68.0)
Known coronary artery disease, n (%) 44 (58.7)
Previous PCI, n (%) 27 (36.0)
Atrial fibrillation, n (%) 11 (14.7)
Left ventricular ejection fraction less than 50%, n (%) 26 (36.6)
Chronic obstructive pulmonary disease, n (%) 11 (14.7)
Previous cerebrovascular disease, n (%) 6 (8.0)
Previous pacemaker implant, n (%) 8 (10.7)
Previous ICD implant, n (%) 0 (0)
Clinical presentation
Dyspnoea, n (%) 64 (85.3)
NYHA III and IV, n (%) 45 (60.0)
Angina, n (%) 10 (13.3)
Syncope, n (%) 3 (4.0)
Cardiogenic shock, n (%) 3 (4.0)
Echocardiographic data
LVEF, % 51.112.0
Peak AV gradient, mmHg 72.225.3
Mean AV gradient, mmHg 47.117.7
Anatomic aortic valve area, cm2 0.70.2
Preoperative surgical risk
Euroscore I logistic 14.76 [IQR 8.46–22.0]
Euroscore I linear 10.00 [IQR 8.00–11.00]
Euroscore II 3.6 [IQR 1.93–6.65]
STS score 3.7 [IQR 2.47–5.95]
AV, Aortic Valve; eGFR, estimated glomerular filtration rate; ICD, Implantable
Cardioverter Device; LVEF, left ventricular ejection fraction; NYHA, New York
Heart Association class; PCI, percutaneous coronary interventions; STS, Society
of Thoracic Surgeons’ risk score.
Table 2 Transcatheter aortic valve implantation procedural
parameters
Procedural parameters
Procedural time, min 101.734.0
Contrast volume, ml 350 [IQR 250.0–442.5]
Access type
Transfemoral, n (%) 69 (92.0)
Direct aortic, n (%) 4 (5.3)
Transapical, n (%) 2 (2.7)
Type of valve
Balloon expandable, n (%) 29 (38.6)
Edwards Sapien 3 29
Self expandable, n (%) 46 (62.4)
Medtronic Corevalve 14
Medtronic Evolut R 14
BSC Lotus 13
Symetis Accurate 4
Jenavalve 1
Procedural complications
Cardiac tamponade, n (%) 1 (1.3)
Hemodynamic instability requiring resuscitation, n (%) 1 (1.3)
Access vessel complication, n (%) 2 (2.6)
Valve in valve, n (%) 3 (3.9)
Intraprocedural death, n (%) 1 (1.3)
© 2018 Italian Federation of Cardiology - I.F.C. All rights reserved.
pulmonary angio CT in 4, chest CT in 2, abdominal CT
scan in 6 patients). The median effective-dose derived
from preprocedural and postprocedural CT examination
amounted to 8.9mSv [IQR 8.0–13.5], almost 25% of the
total exposure.
Coronary angiography and/or PCI performed either
before or after TAVI represented the third source of
exposure with a median effective-dose of 7.86mSv
[IQR 3.80–16.75].
Data regarding radiological exposure derived from pace
maker implantations as well as from standard radiological
exams are reported inTable 3,whereasFig. 2 describes the
relative impact on total exposure according to the source.
During hospitalization or at 1-month follow-up, none of
the patients showed signs suggestive of deterministic
effects (skin erythema, irreversible skin damage, chest
hair loss or cataract) related to the periprocedural or
intraprocedural radiological exposure.
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Table 3 Radiological exposure
Total exposure
Additive effective-dose, mSv 41.39 [IQR 27.93–60.88]
Patients with total dose exceeding
100 mSv, n (%)
10 (13.3)
Procedural exposure during TAVI
Fluoro time, min 23.3 [IQR 18.7–27.5]
Effective-dose, mSv 16.11 [IQR 10.54–27.70]
Nonprocedural-related exposure
Coronary angiographies/PCI, n (%) 74 (98.6)
Total fluoro time, min 8.50 [IQR 4.93–14.48]
Effective-dose, mSv 7.86 [IQR 3.80–16.75]
Cardiac CT scans 66 (88.0)
Effective-dose, mSv 8.56 [IQR 7.40–9.26]
Other CT scansa, n (%) 17 (22.6)
Other CT scan derived effective-dose, mSv 4.5 [IQR 2.1–9.3]
Total CT scan derived effective-dose, mSv 8.9 [IQR 8.0–13.5]
Permanent pacemaker implants, n (%) 12 (16.0)
Total fluoro time, min 4.662.20
Effective-dose, mSv 3.8 [IQR 2.79–4.5]
Standard radiological examinations, n (%) 70 (93.3)
Effective-dose, mSv 0.18 [IQR 0.11–0.34]
CT, computed tomography. a Chest CT/brain CT/abdomen CT scans.
Fig. 1
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Correlates of total radiological exposure
Table 4 reports the results of the univariable and multi-
variable analysis. Male sex (coefficient 0.383, 95% CI
0.022–0.745; P¼ 0.010), and reduced left ventricular
ejection fraction (LVEF < 50%; coefficient 0.497, 95%
CI 0.117–0.876; P¼ 0.011) were associated with
increased total additive effective-dose (log-transformed),
whereas age (per year) was inversely correlated
Radiological exposure of patients undergoing TAVI Biasco et al. 583
Fig. 2
Standard radiological
examinations
PM implants
CT scans
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24.5%
47%
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Angiographies
TAVR
Relative impact of each exam/procedure on total exposure.
Table 4 Univariable and multivariable analysis
Univariable Multivariable
Variable Coefficient 95% Confidence interval P Coefficient 95% Confidence interval P
Male 0.383 0.022–0.745 0.010 0.221 0.136 to 0.578 0.221
Age 0.038 0.068 to 0.009 0.010 0.031 0.060 to 0.002 0.031
BMI >30 0.381 0.025 to 0.788 0.065 0.342 0.091 to 0.776 0.120
Diabetes 0.345 0.045 to 0.736 0.083 0.191 0.258 to 0.641 0.398
Hypertension 0.255 0.337 to 0.848 0.394
Dyslipidaemia 0.301 0.086 to 0.690 0.126
Known CAD 0.254 0.114 to 0.623 0.173
History of PCI 0.107 0.275 to 0.490 0.578
History of atrial fibrillation 0.004 0.524 to 0.515 0.986
COPD 0.096 0.423 to 0.615 0.714
Previous pace maker 0.141 0.737 to 0.453 0.637
End stage renal failure 0.375 1.226 to 1.978 0.642
History of CVA 0.614 1.227 to 0.048 0.069 0.525 1.039 to 0.010 0.046
Mean aortic gradient 0.004 0.015 to 0.006 0.403
LVEF <50% 0.497 0.117–0.876 0.011 0.430 0.031 to 0.829 0.035
Dyspnoea 0.221 0.296 to 0.739 0.397
Stable angina 0.240 0.778 to 0.298 0.377
Syncope 0.087 0.851 to 1.026 0.854
Cardiogenic shock 0.050 0.889 to 0.989 0.915
Transfemoral access 0.381 0.301 to 1.064 0.269
Balloon expandable 0.065 0.454 to 0.324 0.740
Valve in Valve 0.300 1.250 to 0.649 0.530
TAVI procedural time 0.002 0.002 to 0.008 0.301
Logistic ES I 0.003 0.008 to 0.015 0.590
Linear ES I 0.015 0.049 to 0.079 0.634
Euroscore II 0.013 0.016 to 0.042 0.382
STS score 0.000 0.040 to 0.039 0.981
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accidents; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary interventions; TAVI,
transcatheter aortic valve implantation. Statistically significant values in bold.
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(coefficient0.038, 95%CI0.068 to0.009; P¼ 0.010).
BMI greater than 30, diabetes and history of cerebrovas-
cular accidents (CVA) were borderline nonsignificant.
The implantation of balloon expandable as compared
to self expandable valves did not result in an
increased dose.
At multivariable analysis, age (per year, coefficient
0.031, 95% CI 0.060 to 0.002; P¼ 0.031) and previ-
ous history of CVA (coefficient0.545; 95% CI1.039 to
0.010; P¼ 0.046) resulted as inversely correlated to total
effective-dose (log transformed), whereas LVEF less
than 50% (coefficient 0.430, 95% CI 0.031–0.828;
P¼ 0.035) was directly associated.
Discussion
The main findings of our study are as follows:
(1) Multiple radiological exams and procedures are
responsible for the exposure observed in TAVI
patients, with implant procedure being the
prominent source.
(2) Age is inversely related to the radiological exposure,
with younger patients receiving higher doses.
Our article reports not only the intraprocedural data but
also the detailed quantification of the total TAVI-
related burden of X-ray exposure including the prepro-
cedural work-up, the implant and the postprocedural
phase. In addition, predictors of increased exposure
were identified.
Our data revealed that a significant X-ray exposure of
patients treated with TAVI derives from multiple
sources. A median of 16.1mSv was delivered to patients
during the implant, accounting for almost 50% of the total
exposition and in line with previous reports.10 Putting
those data into perspective, this exposure is comparable
with the average 19.4mSv individual cumulative dose of
nuclear plant employees received over their entire
career.15
Such a significant exposure represents a clear indication
for the development and the implementation of institu-
tional low-dose protocols to minimize procedural expo-
sure leading to a significant reduction in exposure during
percutaneous coronary interventions.16
Nonetheless, although being the most important source
of X-ray, TAVI implant represents just one of different
sources to which patients are exposed during the pre-
procedural work-up or the postimplant phase. A median
additive effective-dose of 41.39mSv was measured in our
population with almost 15% of patients exposed to a total
dose exceeding 100mSv. This massive exposure has
been recognized to induce deterministic effects and to
significantly increase by 10% the relative risk of solid
cancers and by 19% of leukaemia in a large dosimetric
study.15
Thus, optimization of the radiological exposure should not
be limited to the implant procedure but extended to the
entire preprocedural work-up and postprocedural phase.
In fact, common practice is to evaluate all patients under-
going TAVI with both a coronary angiogram and an ECG-
gated angio CT for annularmeasurement. As evident from
ourdata, only less than 60%ofpatients had a knownhistory
of coronary artery disease, whereas the remaining could
have been screened for by careful analysis of the angio CT
scan, scheduling for invasive angiography only thosewith a
clear suspicion of significant coronary disease. Accurate
analysis of CT scan data has shown a high sensitivity and
negative predictive value in excluding obstructive coro-
nary artery disease, thus avoiding the need for preproce-
dural angiographic examination in TAVI candidates with
nonobstructive disease at preprocedural CT scan.17,18
Not surprisingly, patient’s age resulted inversely corre-
lated with total exposure, meaning that younger patients
are those receiving greater doses. Our data demonstrate
that a reduction of 10 years in age corresponds to a 30%
increase of the log-dose, thus with a potential detrimental
long-termeffect for youngerpatients.This evidencemight
be a consequence of several concomitant factors such as
the desire of obtaining a more extended revascularization
prior to the TAVI procedure, the possibility to perform
multiple percutaneous procedures, or a preserved renal
function thus allowing a more liberal adoption of prepro-
cedural CT scans or angiographic examinations. Nonethe-
less, because of the retrospectivenatureof our analysis, any
potential implication remains speculative.
Risk of fatal and nonfatal malignancies associated with
radiological exposures in TAVI might represent a negli-
gible hazard whether observed from a local standpoint.
Nonetheless, if considered from a continental or global
perspective, tangible effects of this exposure might
become already manifest at the present stage, with a
current volume of TAVI procedures estimated to be of
more than 70 000 so far19 and with a trend expected to
skyrocket in the next future.
Limitations
The retrospective nature of our work does not allow the
drawing of definite conclusions but data have to be
considered as hypothesis-generating and the small sam-
ple size might impact on dose estimations.
Moreover, evaluation of the effective dose for TAVI
procedures is based on several assumptions and is thus
associated with uncertainties in dose estimates, so this
should be considered as approximations to guide clinical
decision. Finally, although this article aims at sensitizing
the cardiological community on the patient’s related risks
associated with radiological exposure, evaluation of the
professional exposure is beyond our scope.
In conclusion, this is the first report giving a total estima-
tion of the radiological exposure and of the exposure-
584 Journal of Cardiovascular Medicine 2018, Vol 19 No 10
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related risk of fatal lung cancer derived from a contem-
porary TAVI series.
Present data allow the rationalizing of exposure of TAVI
patients, to extend information given to patients prior to
the procedure in terms of additive radiological risk, as
well as to increase the awareness of the cardiological
community towards this significant source of exposure
aiming at protecting patients and health professionals.
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